Physician profile
Zsila S Sadighi
NPI 1750665048
$361,068.16
in general payments reported to CMS, 2019-2025
7 companies · $249K in 2025
The $249K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $4,848 · 2021: $4,311 · 2023: $2,700 · 2024: $100K · 2025: $249K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $288K · Travel and Lodging: $53K · Food and Beverage: $8,186 · Consulting Fee: $3,120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $287,705.00 |
| Travel and Lodging | $52,741.90 |
| Food and Beverage | $8,185.52 |
| Consulting Fee | $3,120.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $228,322.69 | 2023-2025 | Koselugo, Strensiq |
| Springworks Therapeutics, INC. | $123,295.68 | 2025 | Gomekli, Ogsiveo |
| Astrazeneca Pharmaceuticals Lp | $9,159.00 | 2020-2021 | |
| Sk Life Science, INC. | $134.05 | 2025 | |
| Greenwich Biosciences, INC. | $130.59 | 2019 | |
| Allergan, INC. | $26.15 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zsila Sadighi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.